Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study (Q58204616)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Yoshiya Tanaka

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

David Close

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Alex Godwood

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Chi-Yuan Wu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Didier Saurigny

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

11 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

21-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Evolution of treatment for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

The Japanese experience with biologic therapies for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

GM-CSF as a therapeutic target in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Long-term remission of neutropenia in Felty's syndrome after a short GM-CSF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

Current treatments of rheumatoid arthritis: from the 'NinJa' registry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.896448

10.3109/14397595.2014.896448

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24720551%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference